Toward linking structure with function in ATP-sensitive K+ channels

Diabetes

Volumn 53, Issue SUPPL. 3, 2004, Pages

  Bryan, Joseph ^a   Vila Carriles, Wanda H ^a   Zhao, Guiling ^a   Babenko, Audrey P ^a   Aguilar Bryan, Lydia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; CELL PROTEIN; CYTOPLASMIC LO LINKER PROTEIN; GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; LIPID A; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHANNEL GATING; CONFERENCE PAPER; HYDROPHOBICITY; MEMBRANE STRUCTURE; MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTEIN CONFORMATION;

EID: 9444260483     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.suppl_3.S104     Document Type: Conference Paper

References (98)

1. Loubatieres A: The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1955. Ann N Y Acad Sci 71:4-11, 1957
2. Loubatieres A: The discovery of hypoglycemic sulfonamides and particularly of their action mechanism. Acta Diabet Lat 6:20-56, 1969
3. Henquin JC: The fiftieth anniversary of hypoglycaemic sulphonamides: how did the mother compound work? Diabetologia 35:907-912, 1992
4. Henquin JC: Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia 18:151-160, 1980
5. 2+ as evidences in single pancreatic islets. J Biol Chem. 268:22265-22268, 1993
6. 2+ and insulin release in glucose-stimulated pancreatic islets. J Biol Chem 269:8749-8753, 1994
7. Aguilar-Bryan L, Bryan J: Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 20:101-135, 1999
8. Bryan J, Aguilar-Bryan L: Sulfonylurea receptors, ATP-sensitive potassium channels and insulin secretion. In Diabetes Mellitus. 3rd ed. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott Williams & Wilkins, 2004, p. 69-98
9. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M: A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 361:301-307, 2003
10. ATP channels induces profound neonatal diabetes. Cell 100:645-654, 2000
11. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Moines J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhyn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838-1849, 2004
12. Ribalet B, John SA, Weiss JN: Molecular basis for Kir6.2 channel inhibition by adenine nucleotides. Biophys J 84:266-276, 2003
13. ATP pores define a novel gatekeeper. J Biol Chem 278:41577-41580, 2003
14. IR6.2 sensitizes pancreatic beta-cell ATP-sensitive potassium channels toward activation through nucleoside diphosphates. Diabetes 51 (Suppl. 3):S363-S367, 2002
15. Schwanstecher C, Schwanstecher M: Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes. Diabetes 51 (Suppl. 3):S358-S362, 2002
16. + channels. Diabetes 51:875-879, 2002
17. Riedel MJ, Boora P, Steckley D, de Vries G, Light PE: Kir6.2 polymorphisms sensitize beta-cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes? Diabetes 52:2630-2635, 2003
18. IR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia 41:1511-1515, 1998
19. Gloyn AL, Hashim Y, Ashcroft SJ, Ashfleld R, Wiltshire S, Turner RC: Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). Diabet Med 18:206-212, 2001
20. + channel in the beta-cell. Diabetes 51:3135-3138, 2002
21. ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ1 E23K variant is associated with type 2 diabetes. Diabetes 52:568-572, 2003
22. Love-Gregory L, Wasson J, Lin J, Skolnick G, Suarez B, Permutt MA: E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of type II diabetes in Caucasians as the PPARgamma Pro12Ala variant. Diabetologia 46:136-137, 2003
23. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, Thorsteinsson B, Borch-Jonnsen K, Hansen T, Pedersen O: The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 52:573-577, 2003
24. Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM: Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in white Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia 39:1233-1236, 1996
25. + channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes 46:502-507, 1997
26. ATP channel subunits. J Biol Chem 279:9080-9090, 2004
27. ATP channels. Neuron 22:537-548, 1999
28. + channel with an ABC transporter. Neuron 26:155-167, 2000
29. Yuan H, Michelsen K, Schwappach B: 14-3-3 dimers probe the assembly status of multimeric membrane proteins. Curr Biol 13:638-646, 2003
30. ATP channel-independent regulation of insulin secretion. J Biol Chem 275:9270-9277, 2000
31. Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA: Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 277:37176-37183, 2002
32. + channels in the absence of the sulphonylurea receptor. Nature 387:179-183, 1997
33. ATP channels. FEBS Lett 445:131-136, 1999
34. Nichols CG, Shyng SL, Nestorowicz A, Glaser B, Clement IV JP, Gonzalez G, Aguilar-Bryan L, Permutt MA, Bryan J: Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 272:1785-1787, 1996
35. ATP channel activation by Mg-ADP and diazoxide. EMBO J 16:1145-1152, 1997
36. + channels. Neuron 16:1011-1017, 1996
37. + channel. J Biol Chem 271:24321-24324, 1996
38. ATP channel isoforms. J Biol Chem 274:11587-11592, 1999
39. ATP channels. J Biol Chem 276:49083-49092, 2001
40. ATP channels. Ann Rev Physiol 60:667-687, 1998
41. Nichols CG, Lopatin AN: inward rectifier potassium channels. Annu Rev Physiol 59:171-191, 1997
42. Nishida M, MacKinnon R: Structural basis of inward rectification: cytoplasmic pore of the G protein-gated inward rectifier GIRK1 at 1.8 Å resolution. Cell 111:957-965, 2002
43. + conduction and selectivity. Science 280:69-77, 1998
44. Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, Cuthbertson J, Ashcroft FM, Ezaki T, Doyle DA: Crystal structure of the potassium channel KirBac1.1 in the closed state. Science 300:1922-1926, 2003
45. Capener CE, Proks P, Ashcroft FM, Sansom MS: Filter flexibility in a mammalian K channel: models and simulations of Kir6.2 mutants. Biophys J 84:2345-2356, 2003
46. + channel Kir6.2. J Physiol 552:23-34, 2003
47. + channel-Fab complex at 2.0 Å resolution. Nature 414:43-48, 2001
48. Cortes DM, Cuello LG, Perozo E: Molecular architecture of full-length KcsA: role of cytoplasmic domains in ion permeation and activation gating. J Gen Physiol 117:165-180, 2001
49. Dean M, Allikmets R: Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33:475-479, 2001
50. Chang G, Roth CB: Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293:1793-1800, 2001
51. Locher KP, Lee AT, Rees DC: The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 296:1091-1098, 2002
52. Chang G: Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. J Mol Biol 330:419-430, 2003
53. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van Deemter L, Borst P, Varadi A, Sarkadi B: Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273:32167-32175, 1998
54. Bakos E, Evers R, Calenda G, Tusnady GE, Szakacs G, Varadi A, Sarkadi B: Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J Cell Sci 113 Pt 24:4451-4461, 2000
55. Cole SP, Deeley RG: Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20:931-940, 1998
56. Westlake CJ, Qian YM, Gao M, Vasa M, Cole SP, Deeley RG: Identification of the structural and functional boundaries of the multidrug resistance protein 1 cytoplasmic loop 3. Biochemistry 42:14099-14113, 2003
57. Mason DL, Michaelis S: Requirement of the N-terminal extension for vacuolar trafficking and transport activity of yeast Ycf1p, an ATP-binding cassette transporter. Mol Biol Cell 13:4443-4455, 2002
58. Chan KW, Zhang H, Logothetis DE: N-terminal transmembrane domain of the SUR controls trafficking and gating of Kir6 channel subunits. EMBO J 22:3833-3843, 2003
59. ATP channel subunits. Neuron 18:827-838, 1997
60. ATP channel complex. J Gen Physiol 110:655-664, 1997
61. + channel. FEBS Lett 409:232-236, 1997
62. Lu Z, Klem AM, Ramu Y: Ion conduction pore is conserved among potassium channels. Nature 413:809-813, 2001
63. ATP channel. Biochem Soc Trans 30:323-327, 2002
64. IR6.2 peptide. Defining intersubunit gating interactions. J Biol Chem 277:43997-44004, 2002
65. ATP channels. Biochem Biophys Res Commun 255:231-238, 1999
66. ATP channels: control of nucleotide sensitivity by the N-terminal domain of the Kir6.2 subunit. J Physiol (Lond) 515:19-30, 1999
67. Reimann F, Tucker SJ, Proks P, Ashcroft FM: Involvement of the N-terminus of Kir6.2 in coupling to the sulphonylurea receptor. J Physiol 518(Pt 2):325-336, 1999
68. ATP channel inhibition by ATP. EMBO J 17:3290-3296, 1998
69. ATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit. Proc Natl Acad Sci USA 95:13953-13958, 1998
70. ATP channel inhibition by ATP. Biophys J 79:841-852, 2000
71. Trapp S, Haider S, Jones P, Sansom MS, Ashcroft FM: Identification of residues contributing to the ATP binding site of Kir6.2. EMBO J 22:2903-2912, 2003
72. 4 channels display distinct conductivities but uniform ATP inhibition. J Biol Chem 275:31563-31566, 2000
73. ATP channel closure. FEBS Lett 459:367-376, 1999
74. Grell W, Hurnaus R, Griss G, Sauter R, Rupprecht E, Mark M, Luger P, Nar H, Wittneben H, Muller P: Repaglinide and related hypoglycemic benzoic acid derivatives. J Med Chem 41:5219-5246, 1998
75. Gutsche K, Schroder E, Rufer C, Loge O: New hypoglycemic benzenesulfonamido-pyrimidines N-substituted 4-N-(2-pyrimidinyl) sulfonyl-phenylacetamides. Arzneimittelforschung 24:1028-1039, 1974
76. Rufer C, Biere H, Ahrens H, Loge O, Schroder E: Blood glucose lowering sulfonamides with asymmetric carbon atoms. J Med Chem 17:708-715, 1974
77. Biere H, Rufer C, Ahrens H, Loge O, Schroder E: Blood glucose lowering sulfonamides with asymmetric carbon atoms. J Med Chem 17:716-721, 1974
78. Meyer M, Chudziak F, Schwanstecher C, Schwanstecher M, Panten U: Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes. Br J Pharmacol 128:27-34, 1999
79. +-channels by a sulfonylurea analogue with a phosphate group. Biochem Pharmacol 65:599-602, 2003
80. Rufer C, Losert W: Blood glucose lowering sulfonamides with asymmetric carbon atoms. 3. Related N-substituted carbamoylbenzoic acids. J Med Chem 22:750-752, 1979
81. ATP channels. Curr Pharma Design. In press
82. ATP channel. Diabetes 48:1341-1347, 1999
83. Hambrock A, Loffler-Walz C, Russ U, Lange U, Quast U: Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes. Mol Pharmacol 60:190-199, 2001
84. Chen J, Lu G, Lin J, Davidson AL, Quiocho FA: A tweezers-like motion of the ATP-binding cassette dimer in an ABC transport cycle. Mol Cell 12:651-661, 2003
85. + channel currents expressed in Xenopus oocytes: a reinterpretation. J Physiol 504:35-45, 1997
86. Ueda K, Komine J, Matsuo M, Seino S, Amachi T: Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. Proc Natl Acad Sci USA 96:1268-1272, 1999
87. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement IV JP, Boyd III AE, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA: Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268:423-426, 1995
88. Schwanstecher M, Loser S, Chudziak F, Bachmann C, Panten U: Photoaffinity labeling of the cerebral sulfonylurea receptor using a novel radioiodinated azidoglibenclamide analogue. J Neurochem 63:698-708, 1994
89. Schwanstecher M, Loser S, Chudziak F, Panten U: Identification of a 38-kDa high affinity sulfonylurea-binding peptide in insulin-secreting cells and cerebral cortex. J Biol Chem 269:17768-17771, 1994
90. ATP channel. FEBS Lett 499: 154-160, 2001
91. + channel openers. J Biol Chem 275:717-720, 2000
92. Dabrowski M, Ashcroft FM, Ashfield R, Lebrun P, Pirotte B, Egebjerg J, Bondo Hansen J, Wahl P: The novel diazoxide analog 3-isopropylamino-7-methoxy- 4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes 51:1896-1906, 2002
93. Uhde I, Toman A, Gross I, Schwanstecher C, Schwanstecher M: Identification of the potassium channel opener site on sulfonylurea receptors. J Biol Chem 274:28079-28082, 1999
94. ATP channel openers. EMBO J 19:6644-6651, 2000
95. Dickinson KE, Bryson CC, Cohen RB, Rogers L, Green DW, Atwal KS: Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes. Mol Pharmacol 52:473-481, 1997
96. Schwanstecher M, Sieverding C, Dorschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J: Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 17:5529-5535, 1998
97. ATP channel modulator binding to the recombinant sulphonylurea receptor, SUR2B. Br J Pharmacol 125:577-583, 1998
98. 2+. Br J Pharmacol 139:368-380, 2003